MedTrace Logo

Nevirapine / Lamivudine for HIV Maintenance Therapy

NCT07014189 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2025-06-10

No results posted yet for this study

Summary

The standard treatment for HIV infection involves taking a combination of three HIV drugs. The main reason for using multiple substances is to prevent resistance from developing rapidly when only one or two drugs are used.

However, in recent years, studies have shown that the risk of resistance developing is significantly lower once viral replication in the body has been completely suppressed. Studies have now been conducted on this maintenance therapy phase, which aims to reduce the number of drugs used.

Some positive results have been reported with monotherapy. There have been positive results with both protease and integrase inhibitors. However, both groups of drugs demonstrate monotherapy failure in 10-20% of patients. We suspect that poor penetration into the genital tract and brain is partly responsible for this.

In contrast, recent studies on the dual combination of protease or integrase inhibitors with lamivudine have demonstrated excellent efficacy. Lamivudine is known to work very well in the brain and genital tract. Since HIV medication must be taken for life, simplifying therapy is very important. This reduces the potential for long-term side effects and costs.

The Clinic for Infectious Diseases and Hospital Hygiene at the Cantonal Hospital of St. Gallen in Switzerland has many years of experience with nevirapine, an HIV medication introduced over 20 years ago. One third of patients are treated with this substance. Of the additional preparations used in combination with nevirapine, one contains lamivudine (or its analogue, emtricitabine), plus either abacavir or tenofovir. The latter two have potentially significant long-term side effects, including an increased risk of cardiovascular disease and kidney/bone toxicity.

A dual combination of nevirapine and lamivudine is highly likely to be effective. Furthermore, it is the most favourable of all the alternative combinations. Based on current knowledge, this combination appears to have no long-term side effects.

After conducting a controlled pilot study with 20 patients at the KSSG (Kahlert, 2020, https://doi.org/10.1371/journal.pone.0237770), data was obtained showing that the combination of nevirapine and lamivudine is effective in maintaining viral suppression. None of the patients experienced 'viral blips' (temporarily detectable virus concentrations of 50-200 HIV RNA copies/ml of blood), which are known to occur in monotherapy studies. After an observation period of 72-96 weeks, all patients showed sustained stable viral suppression (\<50 HIV RNA copies/ml of blood).

The aim of this study is to evaluate the dual combination of nevirapine and lamivudine in a multicentre setting. The intervention involves switching well-selected patients with no history of treatment failure who have been on long-term, stable, well-suppressed HIV therapy with nevirapine from triple combination therapy to nevirapine plus lamivudine. The study is a non-inferiority trial compared to a virtual control group receiving stable standard combination therapy with 0% treatment failure.

The primary outcome parameter used to assess the non-inferiority of the dual combination is the proportion of patients experiencing treatment failure, as determined by a viral load of ≥200 HIV RNA copies/ml at weeks 6, 12, 24, 36 and 48 of treatment.

Conditions

  • HIV Infection
  • Antiretroviral Treatment
  • Maintenance Therapy

Interventions

DRUG

Neviparine (NVP)/ Lamivudine (3TC)

Treatment with nevirapine (400mg retard) and lamivudine (300mg) once daily

Sponsors & Collaborators

  • Cantonal Hospital of St. Gallen

    lead OTHER

Principal Investigators

  • Pietro Vernazza, Professor · Cantonal Hospital St. Gallen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-12
Primary Completion
2023-01-10
Completion
2023-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07014189 on ClinicalTrials.gov